Systemic Sclerosis: Clinical Trials

9 trials for Systemic Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 terminated. 9 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Terminated 9
Phase 12Terminated 2
Phase 31Terminated 1

Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
KYV-101, Standard lymphodepletion regimen - Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous
Phase 1 / Phase 2TerminatedKyverna Therapeutics32024-08-062026-08-31
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Riociguat Oral Tablet, Placebo - Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Phase 2TerminatedHeidelberg University352022-10-242026-01-21
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
Ixazomib - Systemic Sclerosis, Scleroderma
Phase 2TerminatedMichael M. Pham42021-04-282025-04-06
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
GLPG1690 - Systemic Sclerosis
Phase 2TerminatedLakefront Biotherapeutics NV312019-07-182022-03-29
Cardiac Safe Transplants for Systemic Sclerosis
Rituximab, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Scleroderma
Phase 2 / Phase 3TerminatedNorthwestern University92018-05-172020-08-12
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
Pomalidomide (CC-4047), Placebo - Scleroderma, Systemic, Sclerosis, Systemic
Phase 2TerminatedCelgene232012-08-092023-12-01
Open-Label Study of Oral Treprostinil in Digital Ulcers
treprostinil diethanolamine - Systemic Sclerosis
Phase 2TerminatedUnited Therapeutics1152009-09-012024-06-18
Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
UVA1 - Systemic Scleroderma, Systemic Sclerosis
Phase 1 / Phase 2TerminatedNicolas Hunzelmann92008-02-012017-05-31
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
iloprost, iloprost low dose, iloprost therapy up to 2 ng/kg x min - Systemic Sclerosis
Phase 2TerminatedCharite University, Berlin, Germany501997-09-012008-02-25

Narrower conditions

Scleroderma, Systemic (9)  ·  Scleroderma, Diffuse (4)  ·  Lung Diseases, Interstitial (2)  ·  digital ulcers (2)  ·  Autoimmune Diseases (1)  ·  Familial Primary Pulmonary Hypertension (1)  ·  Hypertension, Pulmonary (1)  ·  Pulmonary Fibrosis (1)  ·  Vascular Diseases (1)

Broader conditions

Connective Tissue Diseases (9)  ·  Skin Diseases (9)  ·  Skin and Connective Tissue Diseases (9)  ·  Lung Diseases (3)  ·  Respiratory Tract Diseases (3)  ·  Cardiovascular Diseases (2)  ·  Fibrosis (1)  ·  Hypertension (1)  ·  Immune System Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Vascular Diseases (1)

Interventions

Cyclophosphamide (2)  ·  fludarabine (2)  ·  Antilymphocyte Serum (1)  ·  Filgrastim (1)  ·  GLPG1690 (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Iloprost (1)  ·  Immunoglobulins, Intravenous (1)  ·  Mesna (1)  ·  Methylprednisolone (1)  ·  Methylprednisolone Acetate (1)  ·  Methylprednisolone Hemisuccinate (1)  ·  Octagam (1)  ·  Rituximab (1)  ·  Ultraviolet Rays (1)

Sponsors

Celgene (1)  ·  Charite University, Berlin, Germany (1)  ·  Heidelberg University (1)  ·  Kyverna Therapeutics (1)  ·  Lakefront Biotherapeutics NV (1)  ·  Michael M. Pham (1)  ·  Nicolas Hunzelmann (1)  ·  Northwestern University (1)  ·  United Therapeutics (1)

Countries

United States (6)  ·  Germany (4)  ·  United Kingdom (4)  ·  Italy (3)  ·  France (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  Poland (1)  ·  Russia (1)

Top investigators

Gabriela Riemekasten, MD (1)  ·  James Seibold, MD (1)  ·  Michael Pham, MD (1)  ·  Nicolas Hunzelmann (1)  ·  Richard Burt, MD (1)  ·  Shimon Korish, MD (1)

Results publications

PMID 18634152, PMID 32612255, PMID 42457022

NIH funding

2019 (1)